Axes Health has been acquired by ARA

June 2026 — Axes Health has been acquired by Assisted Reproduction Alliance (ARA). The transaction reflects the ongoing consolidation of the European fertility sector and combines Axes Health’s strong position in the Czech Republic and Spain with ARA’s pan-European fertility clinic platform.

Axes Health is a provider of fertility services, delivering well over 5,000 fertility treatment cycles annually. The company operates four state-of-the-art IVF clinics in the Czech Republic and Spain, legislatively advanced and stable markets that have helped make Axes Health a prominent choice for fertility tourism. Its established donor program and in-house egg and sperm banks provide expertise in high-value donor IVF and egg donation services, positioning the company well to benefit from the emerging trend of social freezing. In-house egg banks in both the Czech Republic and Spain offer patients a choice across a diverse range of Northern and Southern European phenotypes, providing a key competitive advantage. With a reputation as a pioneer in IVF treatment, Axes Health has developed a holistic approach that combines proven conception methods with novel technologies and physical and mental wellbeing support.

ARA brings together leading independent fertility clinics across Europe within a platform built on clinical excellence, collaboration and long-term growth. ARA partners with founders, physicians and teams that have built successful clinics, providing operational expertise, resources, investment and shared knowledge to accelerate their ambitions while preserving the qualities that contribute to their success. Its approach combines the strengths of individual clinics through shared best practices, collaborative learning and a focus on delivering better outcomes for patients and teams.

The sellers were private individuals, including the founder and investors who have supported Axes Health throughout its history.

Our role in the transaction

Oaklins’ team in the Czech Republic acted as the sell-side advisor to Axes Health’s private shareholders in this transaction. In April 2025, the team launched an international auction process targeting investors primarily across Europe and the USA. Given Axes Health’s strong position in the Czech Republic and emerging presence in Spain, the process attracted interest from approximately 50 financial and strategic investors. Multiple non-binding offers were received, resulting in a competitive bidding process and several parties progressing to the due diligence phase. During the transaction, the scope evolved from an initial capital raise combined with a partial sell-down by a single shareholder to a full sale process. The transaction was signed in May 2026 and successfully closed in June 2026.